Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Cell & gene therapy

Research Field Cancer

“Curing Cancer? That’s Cute”

| James Strachan

Cell and gene therapies are now considered mainstream therapeutic modalities – with revolutionary potential. But that hasn’t always been the case…

Research Field Pain & critical care

An Osteoarthritic Odyssey

Sitting Down With… Mike Clayman, CEO of Flexion Therapeutics, Inc., Burlington, Massachusetts, USA.

Research Field Cell & gene therapy

A Fighting Chance

| Neil Ebenezer

A new technique shows promising results for patients with sight loss from Leber congenital amaurosis

Research Field Cell & gene therapy

Perusing the Pipeline

| James Strachan

With cell and gene therapies being all the rage, we take a peek at some of the advanced therapies coming down the pipe.

Research Field Cell & gene therapy

Swimming against the nucleotides

| James Bainbridge

Tomorrow’s cures for retinopathies will likely include advanced gene and cell therapies delivered by precision surgery.

Research Field Cell & gene therapy

Now For the High-Hanging Fruit

| Miguel Forte

We should be thrilled with the success of the approved CD-19 CAR-T therapies. But the field is still young, and we are only scratching the surface.

Outside the Lab Professional development

Revolutionizing Medicine – While Learning “Novartian”

| James Strachan

Sitting Down With... Bruce Levine, Professor in Cancer Gene Therapy, Perelman School of Medicine, University of Pennsylvania.

Research Field Neuroscience

Building up to a breakthrough

| Jonathan James

We sat down with David Eidelberg shortly after the publication of his group’s most recent paper in Science Translational Medicine.

Research Field Cell & gene therapy

FDA Quackdown

| James Strachan

Regulators step in to stop stem cell clinics from marketing unproven therapies.

Research Field Cell & gene therapy

Fresher and CRISPR

The promise of genome editing is tempered for genetically heterogeneous diseases – introducing a new approach for rhodopsin-dependent retinitis pigmentosa.


Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register